A comprehensive multicenter real-world study conducted in China has confirmed the clinical effectiveness and safety profile of lorlatinib, a third-generation ALK tyrosine kinase inhibitor, in treating ALK-positive non-small-cell lung cancer (NSCLC) patients, particularly those resistant to earlier-generation therapies. Lorlatinib demonstrates substantial activity in this difficult-to-treat population, bolstering its role as a critical option in targeted lung cancer therapy.